Back to Crohns Disease And Colitis
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00552058

NCT00552058
Completed Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You can be either male or female
  • You must be between 18 and 75 years old (inclusive)
  • You have been officially diagnosed with Crohn's disease
  • Your Crohn's disease is currently considered moderate to severe, based on a specific scoring system called the CDAI (with a score between 225 and 450)
  • You have never previously been treated with a type of medication called anti-TNF drugs (examples include infliximab or adalimumab — confirm with trial site if unsure whether your medication counts)

Who may not be able to join:

  • You have previously taken part in a clinical study involving a drug called certolizumab pegol
  • You do not meet certain general health requirements that are standard for this type of Crohn's disease research (confirm with trial site for the full details of these requirements)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
UCB Pharma
Registry
clinicaltrials_gov
Start date
1 March 2008
Est. completion
1 October 2009

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇨🇱 Chile 🇨🇿 Czechia 🇪🇪 Estonia 🇫🇮 Finland 🇩🇪 Germany 🇭🇺 Hungary 🇮🇱 Israel 🇮🇹 Italy 🇱🇻 Latvia 🇳🇿 New Zealand 🇵🇱 Poland 🇷🇴 Romania 🇷🇺 Russia 🇺🇦 Ukraine 🇺🇸 United States

10 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Percentage of Subjects in Clinical Remission at Week 6

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov